Citi lifts target on Acceleron Pharma


Citi sees good things ahead for Acceleron Pharma (XLRN +2.4%) in 2014, as analyst Yaron Werber reiterates a Buy rating.

"In 2014 we expect multiple catalysts, extensive partnership with Celgene, and clinical data to continue to drive interest," Werber says, adding that Citi sees "data in both MDS and thalassemia [being] released at ASCO and EHA in June."

Price target hiked to $50 from $30.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs